Skip to content

4Accepted Aug 5, 4:57 PM ET

MBX Biosciences (MBX) CMO Azoulay Salomon Sells 370 Shares

MBXMBX Biosciences, Inc.

Accepted (ET)

4:57 PM

Aug 5, 2026

Filed

Aug 5, 2026

Documents

2

Size

16.7 KB

Summary

MBX Biosciences (MBX) CMO Azoulay Salomon Sells 370 Shares

Updated

What Happened
Azoulay Salomon, Chief Medical Officer of MBX Biosciences (MBX), sold 370 shares on August 4, 2026, for a weighted average price of $65.77, generating approximately $24,335. The sale was a sell-to-cover to satisfy tax withholding obligations tied to the vesting of restricted stock units, not an open-market investment decision.

Key Details

  • Transaction date: 2026-08-04 (reported on Form 4 filed 2026-08-05) — filing appears timely.
  • Shares sold: 370; weighted average price reported: $65.77; total value ≈ $24,335.
  • Price range for aggregate sales: $65.21 to $66.43 (shares sold on an aggregate basis for all participants). Reporting person can provide a breakdown of shares sold at each price on request.
  • Reason: Mandatory sell-to-cover to cover taxes on RSU vesting (Footnote F1).
  • Shares owned after transaction: Not specified in the provided filing excerpt.
  • Exhibit/Remarks: Exhibit 24 (Power of Attorney) included.

Context
Sell-to-cover transactions are routine tax-withholding events after equity grants vest and do not necessarily signal the insider’s view on the company’s prospects. For retail investors, outright purchases are generally more informative about insider sentiment than routine sell-to-cover sales.

AI-written summary · check the filing